Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...
The author described in detail the vasculature of several tumours that spontaneously occur in rats, and observed that the vascular architecture of each tumour type ... of an anti-VEGF monoclonal ...
Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...
Two independent studies show that ephrin-B2 controls the internalization and signaling of two types of vascular endothelial growth factor (VEGF) receptors—thereby regulating VEGF-induced ...
D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...
Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...
10d
GlobalData on MSNCStone doses first subject in trial of CS2009 for advanced solid tumoursThe antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results